Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic Therapeutics”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy. ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform. A Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts has been initiated.
{iframe}http://www.prnewswire.com/news-releases/astellas-announces-fda-fast-track-designation-for-asp0892-dna-vaccine-for-mitigation-of-severe-hypersensitivity-reactions-due-to-peanut-allergy-300381485.html{/iframe}